2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-09-15NCT06899126
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCHead and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinomaActive, not recruitingPhase 2 / Phase 32026-05-08NCT06295731